重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌的疗效

Efficacy of Recombinant Human Endostatin Combined with Chemotherapy in the Treatment of Advanced Non⁃small Cell Lung Cancer

目的分析重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌(NSCLC)的疗效。方法选择2018年4月-2020年5月诊治的56例晚期NSCLC者。根据化疗是否联合重组人血管内皮抑素治疗将患者分成对接受一线化疗方案治疗常规组(n=26)和重组人血管内皮抑素联合一线化疗治疗联合组(n=30)。比较两组患者血清肿瘤标志物癌胚抗原(CEA)水平、临床疗效和不良反应。结果随着治疗后时间延长,两组患者治疗后1个月、3个月、6个月CEA水平下降,且联合组患者1个月、3个月、6个月CEA水平低于常规组(P<0.05)。联合组有效率90%高于常规组57.69%(P<0.05)。联合组不良反应率26.67%高于常规组23.08%,差异比较无统计学意义(P>0.05)。结论重组人血管内皮抑素联合化疗治疗晚期非小细胞肺癌患者能在保证治疗安全性基础上显著抑制CEA,进而提高疾病缓解率,推荐使用。

Objective To investigate the efficacy of recombinant human endostatin combined with chemotherapy in the treatment of advanced non⁃small cell lung cancer(NSCL).Methods A total of 56 NSCL patients in our hospital from April 2018 to May 2020 were enrolled,and divided into two groups according to different treatment methods,each with 26 cases.Routine group was given first⁃line chemotherapeutic regimen,while combined group received first⁃line chemotherapeutic reg⁃imen combined with recombinant human endostatin.Then the serum tumor marker carcinoembryonic antigen(CEA)level,clinical efficacy and adverse reactions were compared between groups.Results The CEA levels had a decreasing trend in both groups at 1 month,3 months and 6 months after treatment,and were lower in combined group than in routine group(P<0.05).The clinical efficacy of combined group was significantly higher than that of routine group(90%vs 57.69%,P<0.05),and the adverse reaction rate of combined group was slightly higher than that of control group,with no statistic difference(26.67%vs 23.08%,P>0.05).Conclusion Application of recombinant human endostatin combined with chemotherapy in the treatment of advanced NSCL can effectively and safely reduce the CEA level,with good short⁃term effect.